Azione GENOMIC HEALTH, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati
Strumento inattivo

Altre lingue Genomic Health, Inc.

Azioni

US37244C1018

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
MDxHealth SA acquired Oncotype DX GPS Prostate Cancer Business from Genomic Health, Inc. for approximately $100 million.
Biocartis Group NV and Biocartis and Genomic Health, Inc. Agree to End Collaboration Due to Changed Market Circumstances
Genomic Health, Inc. Announces Executive Changes
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 1000
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600 Health Care
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P 600
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Global BMI Index
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Composite 1500
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P TMI Index
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from S&P Biotechnology Select Industry Index
Genomic Health, Inc.(NasdaqGM:GHDX) dropped from NASDAQ Composite Index
Exact Sciences Corporation completed the acquisition of Exact Sciences Corporation from Baker Bros. Advisors LP and others.
Genomic Health : Stockholders Approve Proposed Acquisition by Exact Sciences
Genomic Health, Inc.(NasdaqGS:GHDX) dropped from NASDAQ Biotechnology Index
Genomic Health Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Genomic Health : New TAILORx Data, Published Today in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy Treatment
Genomic Health, Inc. Announces Results from a New Analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx
Genomic Health : New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
New St. Gallen International Breast Cancer Guidelines Recommends Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage Breast Cancer
WeissLaw LLP Investigates Genomic Health, Inc.
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione
  4. Notizie Genomic Health, Inc.
  5. Altre lingue